Pfizer to Buy NextWave Pharmaceuticals

Health and Healthcare

Published: October 22, 2012 8:59 am

Pfizer Inc. (NYSE: PFE) said today that it will acquire privately held NextWave Pharmaceuticals. NextWave is a specialty pharmaceutical company that focuses on the development and commercialization of products for the treatment of attention deficit/hyperactivity disorder (ADHD) and related central nervous system disorders.

The agreement includes recently FDA approved Quillivant XR, which is the first once-daily liquid ADHD treatment in the United States.

Pfizer previously entered into an option and merger agreement with NextWave and made an option payment of $20 million in the second quarter. Pfizer now is exercising its option to acquire NextWave. Under the terms of the agreement, Pfizer will make a payment to of $255 million to NextWave shareholders when the transaction closes. NextWave shareholders are eligible to receive additional payments of up to $425 million, based on certain sales milestones.

The transaction is expected to close during the fourth-quarter of 2012, subject to regulatory approval.

Analysts expect Pfizer to report lower per-share earnings and revenues when it shares it third-quarter results later this month.

Shares of Pfizer are down fractionally in premarket trading to $25.71. The 52-week range is 18.15 to $26.09 and the mean price target is $27.67.

Get Ready To Retire ^(Sponsored)

Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Get started right here.